Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational pr...
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31...
Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference 1x1 MeetingsDate: Wednesday, May 28, 2025 Location: Minneapolis, MN 45th Annual William Blair Growth Stock Conference Presentation and 1x1 Meetings Date and Time: Wednesday, June 4, 2025 at 9:20 AM CTLocation: Chicago, IL The presentation will be web...
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting in Montreal, Quebec and at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, California. The presentation titled “Time to Diagnosis of Lung Cancer from Identification of a Pulmonary Nodule in the United States” w...
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a . The Top Workplaces program has an 18-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. This recognition is based solely on gathered through a third-party survey, administered by employee engagement technology partner, . The confidential survey uniquely measures the employee experience and its component themes, includi...
Biodesix Announces First Quarter 2025 Results and Highlights Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. “Our quarter was highlighted by continued progres...
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Analysts who wish to participate in the qu...
Brookline Bancorp Announces First Quarter Results Net Income of $19.1 million, EPS of $0.21 Operating Earnings of $20.0 million, Operating EPS of $0.22 Quarterly Dividend of $0.135 BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Brookline Bancorp, Inc. (NASDAQ: BRKL) (the “Company”) today announced net income of $19.1 million, or $0.21 per basic and diluted share, for the first quarter of 2025, compared to net income of $17.5 million, or $0.20 per basic and diluted share, for the fourth quarter of 2024, and $14.7 million, or $0.16 per basic and diluted share, for the first quarter of 2024. ...
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE: BIO), a global leader in life sc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.